| Yazarlar |
Serap YALÇIN AZARKAN
Kırşehir Ahi Evran Üniversitesi, Türkiye |
Seda Yalçınkaya
|
Fahriye ERCAN
Kırşehir Ahi Evran Üniversitesi, Türkiye |
| Özet |
| SARS-Cov-2(Covid-19) is a new strain of coronavirus and was firstly emerged in December 2019 in Wuhan, China. Now, there is no known specific treatment of Covid-19 available. COVID-19 main protease is a potential drug target and is firstly crystallised by Liu et al (2020). In the study, we investigated the drug potential of molecules that the components of an important medicinal plant Passiflora by using molecular docking, molecular dynamic and drug possibility properties of these molecules. Docking performances were done by Autodock. Chloroquine, hydroxychloroquine were used as standarts for comparison of tested ligands. The molecular docking results showed that the Luteolin, Lucenin, Olealonic acid, Isoorientin, Isochaphoside, Saponarin, Schaftoside etc. ligands was bound with COVID-19 main protease above-8,0 kcal/mol binding energy. Besides, ADME, drug-likeness features of compounds of Passiflora were investigated using the rules of Lipinski, Veber, and Chose. According to the results obtained, it has been shown that compounds of Passiflora have the potential to be an effective drug in the COVID-19 pandemic. Further studies are needed to reveal the drug potential of these ligands. Our results will be a source for these studies. (c) 2021 Elsevier B.V. All rights reserved. |
| Anahtar Kelimeler |
| Covid-19 main protease | Passiflora | Molecular docking | Drug-likeness | ADME |
| Makale Türü | Özgün Makale |
| Makale Alt Türü | SSCI, AHCI, SCI, SCI-Exp dergilerinde yayımlanan tam makale |
| Dergi Adı | JOURNAL OF MOLECULAR STRUCTURE |
| Dergi ISSN | 0022-2860 |
| Dergi Tarandığı Indeksler | SCI-Expanded |
| Dergi Grubu | Q3 |
| Makale Dili | Türkçe |
| Basım Tarihi | 09-2021 |
| Cilt No | 1240 |
| Doi Numarası | 10.1016/j.molstruc.2021.130556 |
| Makale Linki | http://dx.doi.org/10.1016/j.molstruc.2021.130556 |
| Atıf Sayıları | |
| WoS | 20 |
| Google Scholar | 31 |
